Assessment of Neutrophil-to-Lymphocyte Ratio as A Prognostic Marker in Locally Advanced Head and Neck Cancer Treated with Concomitant Chemoradiation

[1] Guo K, Xiao W, Chen X, Zhao Z, Lin Y, Chen G. Epidemiological Trends of Head and Neck Cancer: A Population-Based Study. Biomed Res Int. 2021; 2021:1738932. doi: 10.1155/2021/1738932. PMID: 34337000; PMCID: PMC8294963. GuoK XiaoW ChenX ZhaoZ LinY ChenG Epidemiological Trends of Head and Neck Cancer: A Population-Based Study Biomed Res Int. 2021 2021 1738932 10.1155/2021/1738932 34337000 PMC8294963 Open DOISearch in Google Scholar

[2] Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2016; 91(3): 386–96. doi: 10.1016/j.mayocp.2015.12.017. PMID: 26944243. MarurS ForastiereAA Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment Mayo Clin Proc. 2016 91 3 386 96 10.1016/j.mayocp.2015.12.017 26944243 Open DOISearch in Google Scholar

[3] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3): 209–49. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338. SungH FerlayJ SiegelRL LaversanneM SoerjomataramI JemalA Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin. 2021 71 3 209 49 10.3322/caac.21660 Epub 2021 Feb 4. 33538338 Open DOISearch in Google Scholar

[4] Raj S, Kesari KK, Kumar A, Rathi B, Sharma A, Gupta PK et al. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer. Mol Cancer. 2022; 21(1): 31–47. doi: 10.1186/s12943-022-01503-1. PMID: 35081970; PMCID: PMC8790852. RajS KesariKK KumarA RathiB SharmaA GuptaPK Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer Mol Cancer. 2022 21 1 31 47 10.1186/s12943-022-01503-1 35081970 PMC8790852 Open DOISearch in Google Scholar

[5] Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D et al. NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. J Natl Compr Canc Netw. 2022; 20(3): 224–34. doi: 10.6004/jnccn.2022.0016. PMID: 35276673. CaudellJJ GillisonML MaghamiE SpencerS PfisterDG AdkinsD NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022 J Natl Compr Canc Netw. 2022 20 3 224 34 10.6004/jnccn.2022.0016 35276673 Open DOISearch in Google Scholar

[6] Kaidar-Person O, Gil Z, Billan S. Precision medicine in head and neck cancer. Drug Resist Updat. 2018; 40:13–6. doi: 10.1016/j.drup.2018.09.001. Epub 2018 Sep 25. PMID: 30466712. Kaidar-PersonO GilZ BillanS Precision medicine in head and neck cancer Drug Resist Updat. 2018 40 13 6 10.1016/j.drup.2018.09.001 Epub 2018 Sep 25. 30466712 Open DOISearch in Google Scholar

[7] Zhan C, Yang X, Song X, Yan L. Radiotherapy vs surgery for T1-2N0M0 laryngeal squamous cell carcinoma: A population-based and propensity score matching study. Cancer Med. 2018; 7(7): 2837–47. doi: 10.1002/cam4.1525. Epub 2018 May 7. PMID: 29733513; PMCID: PMC6051150. ZhanC YangX SongX YanL Radiotherapy vs surgery for T1-2N0M0 laryngeal squamous cell carcinoma: A population-based and propensity score matching study Cancer Med. 2018 7 7 2837 47 10.1002/cam4.1525 Epub 2018 May 7. 29733513 PMC6051150 Open DOISearch in Google Scholar

[8] Hilal L, Moukarbel R, Ollaik F, Yang P, Youssef B. Patient Selection for Surgery vs Radiotherapy for Early Stage Oropharyngeal Cancer. Cancer Control. 2021;28:10732748211050770. doi: 10.1177/10732748211050770. PMID: 34936505; PMCID: PMC8704187. HilalL MoukarbelR OllaikF YangP YoussefB Patient Selection for Surgery vs Radiotherapy for Early Stage Oropharyngeal Cancer Cancer Control. 2021 28 10732748211050770. 10.1177/10732748211050770 34936505 PMC8704187 Open DOISearch in Google Scholar

[9] Iqbal MS, Chaw C, Kovarik J, Aslam S, Jackson A, Kelly J et al. Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival. Int Arch Otorhinolaryngol. 2017; 21(2): 171–7. doi: 10.1055/s-0036-1594020. Epub 2016 Dec 19. PMID: 28382126; PMCID: PMC5375948. IqbalMS ChawC KovarikJ AslamS JacksonA KellyJ Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival Int Arch Otorhinolaryngol. 2017 21 2 171 7 10.1055/s-0036-1594020 Epub 2016 Dec 19. 28382126 PMC5375948 Open DOISearch in Google Scholar

[10] Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92(1): 4–14. doi: 10.1016/j.radonc.2009.04.014. Epub 2009 May 14. PMID: 19446902. PignonJP le MaîtreA MaillardE BourhisJ MACH-NC Collaborative Group Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients Radiother Oncol. 2009 92 1 4 14 10.1016/j.radonc.2009.04.014 Epub 2009 May 14. 19446902 Open DOISearch in Google Scholar

[11] Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS et al; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021;156: 281–93. doi: 10.1016/j.radonc.2021.01.013. Epub 2021 Jan 27. PMID: 33515668; PMCID: PMC8386522. LacasB CarmelA LandaisC WongSJ LicitraL TobiasJS MACH-NC Collaborative Group Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group Radiother Oncol. 2021 156 281 93 10.1016/j.radonc.2021.01.013 Epub 2021 Jan 27. 33515668 PMC8386522 Open DOISearch in Google Scholar

[12] Givens DJ, Karnell LH, Gupta AK, Clamon GH, Pagedar NA, Chang KE et al. Adverse Events Associated With Concurrent Chemoradiation Therapy in Patients With Head and Neck Cancer. Arch Otolaryngol Head Neck Surg. 2009;135(12):1209–17. doi:10.1001/archoto.2009.174 GivensDJ KarnellLH GuptaAK ClamonGH PagedarNA ChangKE Adverse Events Associated With Concurrent Chemoradiation Therapy in Patients With Head and Neck Cancer Arch Otolaryngol Head Neck Surg. 2009 135 12 1209 17 10.1001/archoto.2009.174 Open DOISearch in Google Scholar

[13] Li Y, Jiang Y, Qiu B, Sun H, Wang J. Current radiotherapy for recurrent head and neck cancer in the modern era: a state-of-the-art review. J Transl Med. 2022 Dec 6;20(1):566. doi: 10.1186/s12967-022-03774-0. PMID: 36474246; PMCID: PMC9724430. LiY JiangY QiuB SunH WangJ Current radiotherapy for recurrent head and neck cancer in the modern era: a state-of-the-art review J Transl Med. 2022 Dec 6 20 1 566 10.1186/s12967-022-03774-0 36474246 PMC9724430 Open DOISearch in Google Scholar

[14] Borsetto D, Polesel J, Tirelli G, Menegaldo A, Baggio V, Gava A et al. Pretreatment High MCV as Adverse Prognostic Marker in Nonanemic Patients with Head and Neck Cancer. Laryngoscope. 2021; 131(3):E836–45. doi: 10.1002/lary.28882. Epub 2020 Jun 26. PMID: 32589769. BorsettoD PoleselJ TirelliG MenegaldoA BaggioV GavaA Pretreatment High MCV as Adverse Prognostic Marker in Nonanemic Patients with Head and Neck Cancer Laryngoscope. 2021 131 3 E836 45 10.1002/lary.28882 Epub 2020 Jun 26. 32589769 Open DOISearch in Google Scholar

[15] Wang S, Feng Y, Xie Y, Zhao X, Ma J, Liu X et al. High fibrinogen-albumin ratio index (FARI) predicts poor survival in head and neck squamous cell carcinoma patients treated with surgical resection. Eur Arch Otorhinolaryngol. 2022; 279(9): 4541–8. doi: 10.1007/s00405-022-07391-x. Epub 2022 Apr 24. PMID: 35462579. WangS FengY XieY ZhaoX MaJ LiuX High fibrinogen-albumin ratio index (FARI) predicts poor survival in head and neck squamous cell carcinoma patients treated with surgical resection Eur Arch Otorhinolaryngol. 2022 279 9 4541 8 10.1007/s00405-022-07391-x Epub 2022 Apr 24. 35462579 Open DOISearch in Google Scholar

[16] Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020; 18(1): 360. doi: 10.1186/s12916-020-01817-1. PMID: 33213430; PMCID: PMC7678319. CuppMA CariolouM TzoulakiI AuneD EvangelouE Berlanga-TaylorAJ Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies BMC Med. 2020 18 1 360 10.1186/s12916-020-01817-1 33213430 PMC7678319 Open DOISearch in Google Scholar

[17] Mazaki J, Katsumata K, Kasahara K, Tago T, Wada T, Kuwabara H et al. Neutrophil-to-lymphocyte ratio is a prognostic factor for colon cancer: a propensity score analysis. BMC Cancer. 2020; 20(1): 922. doi: 10.1186/s12885-020-07429-5. PMID: 32977767; PMCID: PMC7519490. MazakiJ KatsumataK KasaharaK TagoT WadaT KuwabaraH Neutrophil-to-lymphocyte ratio is a prognostic factor for colon cancer: a propensity score analysis BMC Cancer. 2020 20 1 922 10.1186/s12885-020-07429-5 32977767 PMC7519490 Open DOISearch in Google Scholar

[18] Pirozzolo G, Gisbertz SS, Castoro C, van Berge Henegouwen MI, Scarpa M. Neutrophil-to-lymphocyte ratio as prognostic marker in esophageal cancer: a systematic review and meta-analysis. J Thorac Dis. 2019;11(7):3136–45. doi: 10.21037/jtd.2019.07.30. PMID: 31463142; PMCID: PMC6688029. PirozzoloG GisbertzSS CastoroC van Berge HenegouwenMI ScarpaM Neutrophil-to-lymphocyte ratio as prognostic marker in esophageal cancer: a systematic review and meta-analysis J Thorac Dis. 2019 11 7 3136 45 10.21037/jtd.2019.07.30 31463142 PMC6688029 Open DOISearch in Google Scholar

[19] Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017; 19(1): 2. doi: 10.1186/s13058-016-0794-1. PMID: 28057046; PMCID: PMC5217326. EthierJL DesautelsD TempletonA ShahPS AmirE Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis Breast Cancer Res. 2017 19 1 2 10.1186/s13058-016-0794-1 28057046 PMC5217326 Open DOISearch in Google Scholar

[20] Magdy M, Hussein T, Ezzat A, Gaballah A. Pre-treatment Peripheral Neutrophil-Lymphocyte Ratio as a Prognostic Marker in Gastric Cancer. J Gastrointest Cancer. 2019; 50(4): 763–8. doi: 10.1007/s12029-018-0144-x. PMID: 30058031. MagdyM HusseinT EzzatA GaballahA Pre-treatment Peripheral Neutrophil-Lymphocyte Ratio as a Prognostic Marker in Gastric Cancer J Gastrointest Cancer. 2019 50 4 763 8 10.1007/s12029-018-0144-x 30058031 Open DOISearch in Google Scholar

[21] Haddad CR, Guo L, Clarke S, Guminski A, Back M, Eade T. Neutrophil-to-lymphocyte ratio in head and neck cancer. J Med Imaging Radiat Oncol. 2015; 59(4): 514–9. doi: 10.1111/1754-9485.12305. Epub 2015 Apr 23. PMID: 25908427. HaddadCR GuoL ClarkeS GuminskiA BackM EadeT Neutrophil-to-lymphocyte ratio in head and neck cancer J Med Imaging Radiat Oncol. 2015 59 4 514 9 10.1111/1754-9485.12305 Epub 2015 Apr 23. 25908427 Open DOISearch in Google Scholar

[22] Rachidi S, Wallace K, Wrangle JM, Day TA, Alberg AJ, Li Z. Neutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma. Head Neck. 2016; 38(Suppl 1): E1068–74. doi: 10.1002/hed.24159. Epub 2015 Sep 28. PMID: 26040762; PMCID: PMC4909151. RachidiS WallaceK WrangleJM DayTA AlbergAJ LiZ Neutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma Head Neck. 2016 38 Suppl 1 E1068 74 10.1002/hed.24159 Epub 2015 Sep 28. 26040762 PMC4909151 Open DOISearch in Google Scholar

[23] Malik A, Mishra A, Mair M, Chakrabarti S, Garg A, Singhvi H et al. Role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in oral cavity cancers. Indian J Med Paediatr Oncol. 2019; 40(1): 94–100. MalikA MishraA MairM ChakrabartiS GargA SinghviH Role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in oral cavity cancers Indian J Med Paediatr Oncol. 2019 40 1 94 100 Search in Google Scholar

[24] Das SM, Singh D, Bose A, Das S, Neena Prasad S, Dastidar AG. Role of systemic inflammatory markers (biomarkers) as important prognostic factors for survival in head and neck cancer. Biomedicine. 2021; 41(4): 837–44. doi: 10.51248/.v41i4.1363 DasSM SinghD BoseA DasS Neena PrasadS DastidarAG Role of systemic inflammatory markers (biomarkers) as important prognostic factors for survival in head and neck cancer Biomedicine. 2021 41 4 837 44 10.51248/.v41i4.1363 Open DOISearch in Google Scholar

[25] Tazzyman S, Niaz H, Murdoch C. Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth. Semin Cancer Biol. 2013; 23(3): 149–58. doi: 10.1016/j.semcancer.2013.02.003. Epub 2013 Feb 11. PMID: 23410638. TazzymanS NiazH MurdochC Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth Semin Cancer Biol. 2013 23 3 149 58 10.1016/j.semcancer.2013.02.003 Epub 2013 Feb 11. 23410638 Open DOISearch in Google Scholar

[26] Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer. 2017; 16(1):137–43. doi: 10.1186/s12943-017-0707-7. PMID: 28810877; PMCID: PMC5558711. OcanaA Nieto-JiménezC PandiellaA TempletonAJ Neutrophils in cancer: prognostic role and therapeutic strategies Mol Cancer. 2017 16 1 137 43 10.1186/s12943-017-0707-7 28810877 PMC5558711 Open DOISearch in Google Scholar

[27] Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007; 117(5): 1137–46. doi: 10.1172/JCI31405. PMID: 17476343; PMCID: PMC1857231. SwannJB SmythMJ Immune surveillance of tumors J Clin Invest. 2007 117 5 1137 46 10.1172/JCI31405 17476343 PMC1857231 Open DOISearch in Google Scholar

[28] Wang X, Zhao Z, Wang P, Geng X, Zhu L, Li M. Low Lymphocyte Count is Associated with Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients. Front Oncol. 2020; 10: 997. doi: 10.3389/fonc.2020.00997. PMID: 32656085; PMCID: PMC7324641. WangX ZhaoZ WangP GengX ZhuL LiM Low Lymphocyte Count is Associated with Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients Front Oncol. 2020 10 997 10.3389/fonc.2020.00997 32656085 PMC7324641 Open DOISearch in Google Scholar

[29] Howard R, Kanetsky PA, Egan KM. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci Rep. 2019; 9: 19673. https://doi.org/10.1038/s41598-019-56218-z HowardR KanetskyPA EganKM Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer Sci Rep. 2019 9 19673 https://doi.org/10.1038/s41598-019-56218-z Search in Google Scholar

[30] Tu XP, Qiu QH, Chen LS, Luo XN, Lu ZM, Zhang SY et al. Preoperative neutrophil-to-lymphocyte ratio is an independent prognostic marker in patients with laryngeal squamous cell carcinoma. BMC Cancer. 2015; 15(1):743–50. doi: 10.1186/s12885-015-1727-6. PMID: 26482899; PMCID: PMC4615885. TuXP QiuQH ChenLS LuoXN LuZM ZhangSY Preoperative neutrophil-to-lymphocyte ratio is an independent prognostic marker in patients with laryngeal squamous cell carcinoma BMC Cancer. 2015 15 1 743 50 10.1186/s12885-015-1727-6 26482899 PMC4615885 Open DOISearch in Google Scholar

[31] Zeng YC, Chi F, Xing R, Xue M, Wu LN, Tang MY et al. Pre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy. Jpn J Clin Oncol. 2016;46(2):126–31. doi: 10.1093/jjco/hyv175. Epub 2015 Nov 25. PMID: 26611205; PMCID: PMC5007580. ZengYC ChiF XingR XueM WuLN TangMY Pre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy Jpn J Clin Oncol. 2016 46 2 126 31 10.1093/jjco/hyv175 Epub 2015 Nov 25. 26611205 PMC5007580 Open DOISearch in Google Scholar

[32] Zhang B, Du W, Gan K, Fang Q, Zhang X. Significance of the neutrophil-to-lymphocyte ratio in young patients with oral squamous cell carcinoma. Cancer Manag Res. 2019; 11:7597–603. doi: 10.2147/CMAR.S211847. PMID: 31496814; PMCID: PMC6691951. ZhangB DuW GanK FangQ ZhangX Significance of the neutrophil-to-lymphocyte ratio in young patients with oral squamous cell carcinoma Cancer Manag Res. 2019 11 7597 603 10.2147/CMAR.S211847 31496814 PMC6691951 Open DOISearch in Google Scholar

[33] Takenaka Y, Kitamura T, Oya R, Ashida N, Shimizu K, Takemura K et al. Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis. PLoS One. 2017; 12(7):e0181478. doi: 10.1371/journal.pone.0181478. PMID: 28715474; PMCID: PMC5513538. TakenakaY KitamuraT OyaR AshidaN ShimizuK TakemuraK Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis PLoS One. 2017 12 7 e0181478 10.1371/journal.pone.0181478 28715474 PMC5513538 Open DOISearch in Google Scholar

[34] Yu Y, Wang H, Yan A, Wang H, Li X, Liu J et al. Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis. BMC Cancer. 2018; 18(1):1–9. https://doi.org/10.1186/s12885-018-4230-z YuY WangH YanA WangH LiX LiuJ Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis BMC Cancer. 2018 18 1 1 9 https://doi.org/10.1186/s12885-018-4230-z Search in Google Scholar

[35] Cho Y, Kim JW, Yoon HI, Lee CG, Keum KC, Lee IJ. The Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Head and Neck Cancer Patients Treated with Radiotherapy. J Clin Med. 2018; 7(12):512–25. doi: 10.3390/jcm7120512. PMID: 30513928; PMCID: PMC6306798. ChoY KimJW YoonHI LeeCG KeumKC LeeIJ The Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Head and Neck Cancer Patients Treated with Radiotherapy J Clin Med. 2018 7 12 512 25 10.3390/jcm7120512 30513928 PMC6306798 Open DOISearch in Google Scholar

[36] Hashemi-Bahremani M, Mortazavi N, Novin K, Ameri A, Razzaghi Z. Blood neutrophil-to-lymphocyte ratio as a predictor of response to chemotherapy in head-and-neck cancers. J Head Neck Physicians Surg. 2019;7(1):20–5. Hashemi-BahremaniM MortazaviN NovinK AmeriA RazzaghiZ Blood neutrophil-to-lymphocyte ratio as a predictor of response to chemotherapy in head-and-neck cancers J Head Neck Physicians Surg. 2019 7 1 20 5 Search in Google Scholar

[37] Gorphe P, Bouhir S, Garcia GCTE, Alali A, Even C, Breuskin I et al. Anemia and neutrophil-to-lymphocyte ratio in laryngeal cancer treated with induction chemotherapy. Laryngoscope. 2020 Apr;130(4):E144–50. doi: 10.1002/lary.28021. Epub 2019 Apr 22. PMID: 31006874. GorpheP BouhirS GarciaGCTE AlaliA EvenC BreuskinI Anemia and neutrophil-to-lymphocyte ratio in laryngeal cancer treated with induction chemotherapy Laryngoscope 2020 Apr 130 4 E144 50 10.1002/lary.28021 Epub 2019 Apr 22. 31006874 Open DOISearch in Google Scholar